RxDoctor Payments Data

Curtis Weiss, MD

Pulmonary Disease · Skokie, ILNPI 1245414432

Payments from drug & device makers

$21,654in general payments, 2019–2025

Across 67 payments — averaging $323.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$13K
  • Sanofi$8K
  • AstraZeneca$330
  • Philips North America LLC$120
  • Genentech USA, Inc.$113
  • Boehringer Ingelheim$76
  • plus $116 from 3 others

What the payments were for

  • Consulting fees$3,73817%
  • Speaking & faculty fees$14,52467%
  • Travel & lodging$9344%
  • Food & beverage$2,45711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,654 in reported general payments places this provider in the 85th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$93,120
Medicare patients
383
Services billed
1,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate22$281,151
Trelegy ElliptaFluticasone/Umeclidin/Vilanter165$130,364
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr140$73,896
Breo ElliptaFluticasone/Vilanterol78$34,346
Incruse ElliptaUmeclidinium Bromide42$17,695
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$16,920
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$15,139
Spiriva HandihalerTiotropium Bromide12$6,262
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$5,218
Albuterol Sulfate HfaAlbuterol Sulfate181$4,543
DuleraMometasone/Formoterol12$3,967
Wixela InhubFluticasone Propion/Salmeterol19$3,210
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$3,027
SymbicortBudesonide/Formoterol Fumarate13$2,811
Advair DiskusFluticasone Propion/Salmeterol16$2,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat$76$298,07148 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$14$256,301425 claims
AstraZenecaBreztri Aerosphere, Symbicort$330$17,95026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Skokie

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →